Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter,Open-label,Exploratory Study of QL1706 Plus Nab-paclitaxel and Gemcitabine With or Without Bevacizumab as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

NCT06313970 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06313970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06313970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter,Open-label,Exploratory Study of QL1706 Plus Nab-paclitaxel and Gemcitabine With or Without Bevacizumab as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 20, 2024
Completion date
June 30, 2027
Enrollment
58 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer